123 related articles for article (PubMed ID: 37690234)
1. A C
Wu H; Yu Y; Zhao Y; Liu W; Liu Z; Zhang G; Chen Z
Int Immunopharmacol; 2023 Nov; 124(Pt A):110904. PubMed ID: 37690234
[TBL] [Abstract][Full Text] [Related]
2. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
3. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
4. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
[TBL] [Abstract][Full Text] [Related]
5. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
6. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
7. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
8. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
[TBL] [Abstract][Full Text] [Related]
9. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
10. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
[TBL] [Abstract][Full Text] [Related]
11. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.
Lai P; Chen X; Wang Y; Wang J; Zhang Y; Geng S; Li P; Du X; Weng J; Pei D
J Hematol Oncol; 2022 May; 15(1):68. PubMed ID: 35597971
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
[TBL] [Abstract][Full Text] [Related]
14. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
15. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
16. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
17. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.
Wu L; Chen J; Cai R; Wang X; Liu Y; Zheng Q; Li L
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345104
[TBL] [Abstract][Full Text] [Related]
18. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.
Riberdy JM; Zhou S; Zheng F; Kim YI; Moore J; Vaidya A; Throm RE; Sykes A; Sahr N; Bonifant CL; Ryu B; Gottschalk S; Velasquez MP
Mol Ther Methods Clin Dev; 2020 Sep; 18():571-581. PubMed ID: 32775492
[TBL] [Abstract][Full Text] [Related]
19. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2021 Nov; 18(11):715-727. PubMed ID: 34230645
[TBL] [Abstract][Full Text] [Related]
20. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Katsarou A; Sjöstrand M; Naik J; Mansilla-Soto J; Kefala D; Kladis G; Nianias A; Ruiter R; Poels R; Sarkar I; Patankar YR; Merino E; Reijmers RM; Frerichs KA; Yuan H; de Bruijn J; Stroopinsky D; Avigan D; van de Donk NWCJ; Zweegman S; Mutis T; Sadelain M; Groen RWJ; Themeli M
Sci Transl Med; 2021 Dec; 13(623):eabh1962. PubMed ID: 34878825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
